The efficacy and safety of sequential use of anlotinib and 131I for locally advanced or metastatic differentiated thyroid cancer: A single-arm phase II clinical trial

被引：0
|
作者：
Song, Hongjun
Qiu, Xian
He, Ziyan
Chen, Libo
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Peoples Hosp 6, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18102
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple-negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
    Li, H.
    Zhou, D.
    Yv, Z.
    Liao, Y.
    Huang, J.
    Sun, S.
    Zheng, F.
    Li, B.
    Fang, S.
    Qiang, L.
    Ren, G.
    Wang, X.
    Zhang, B.
    Fan, B.
    Zhao, X.
    Li, W.
    Wang, Z.
    Fu, H.
    Sun, X.
    Shi, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S368 - S368
  • [43] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Ali A. Mokdad
    Hao Zhu
    Muhammad S. Beg
    Yull Arriaga
    Jonathan E. Dowell
    Amit G. Singal
    Adam C. Yopp
    Targeted Oncology, 2019, 14 : 541 - 550
  • [44] Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.
    Guo, Honghai
    Ding, Ping'an
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Zhang, Ze
    Zheng, Tao
    Zhang, Zhidong
    Wang, Dong
    Tan, Bibo
    Zhao, Xuefeng
    Li, Yong
    Zhao, Qun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16091 - E16091
  • [45] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Mokdad, Ali A.
    Zhu, Hao
    Beg, Muhammad S.
    Arriaga, Yull
    Dowell, Jonathan E.
    Singal, Amit G.
    Yopp, Adam C.
    TARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550
  • [46] Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial
    Xiao, Zhehao
    Chen, Weiling
    Du, Youqin
    Zeng, Fanyan
    Su, Fang
    Huang, Shiting
    Qu, Song
    INTERNATIONAL JOURNAL OF CANCER, 2025,
  • [47] The clinical efficacy and safety of sintilimab plus anlotinib for unresectable intrahepatic cholangiocarcinoma (ICC): A prospective, single-arm phase II study.
    Cheng, Jian-Wen
    Yang, Xin-Rong
    Xu, Yang
    Huang, Xiao-Wu
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
    Grivas, P.
    Sridhar, S.
    Perez Valderrama, B.
    Castellano Gauna, D. E.
    Loriot, Y.
    Doger de Speville, B.
    Pouessel, D.
    van der Heijden, M. S.
    Galsky, M. D.
    Gulati, S.
    Ravaud, A.
    Fontana, E.
    Spira, A. I.
    Gartrell, B. A.
    Mortazavi, A.
    Isambert, N.
    Baxter, D.
    Powles, T. B.
    Khaled, A. H.
    Morales Barrera, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1209 - S1210
  • [49] A Phase II, Single-Arm, Prospective Clinical Trial for the Efficacy and Safety of Apatinib Combined With Capecitabine in Therapy for Recurrent/Metastatic and Persistent Cervical Cancer After Radiochemotherapy
    Li, J.
    Mao, W.
    Li, F.
    Ran, L.
    Chang, J.
    Mei, F.
    Hu, L.
    Du, Y.
    Tian, X.
    Liu, M.
    Chen, Y.
    Shan, L.
    Mu, J.
    Yin, S.
    Qin, Y.
    Liang, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E616 - E617
  • [50] Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
    Hayashida, Tetsu
    Jinno, Hiromitsu
    Mori, Katsuaki
    Sato, Hiroki
    Matsui, Akira
    Sakurai, Takashi
    Hattori, Hiroaki
    Takayama, Shin
    Wada, Masahiro
    Takahashi, Maiko
    Seki, Hirohito
    Seki, Tomoko
    Nagayama, Aiko
    Matsumoto, Akiko
    Kitagawa, Yuko
    BMC CANCER, 2018, 18
12345